HIV and pandemic influenza virus: Two great infectious disease challenges

Virology

Volumn 268, Issue 2, 2000, Pages 227-230

  Ada, Gordon ^a  

^a Biology and Environment   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

VACCINE;

ANTIBODY PRODUCTION; CELLULAR IMMUNITY; EFFECTOR CELL; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNE RESPONSE; INFECTION CONTROL; INFECTION PREVENTION; INFLUENZA VIRUS; NONHUMAN; PRIORITY JOURNAL; SHORT SURVEY; VACCINATION; VIRUS INFECTION;

HUMAN IMMUNODEFICIENCY VIRUS; INFLUENZA VIRUS;

EID: 0034653598     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1006/viro.2000.0207     Document Type: Article

References (6)

1. Ada G., Ramsay A. Vaccines, Vaccination and the Immune Response. 1997;Lippincott-Raven, Philadelphia.
2. Kent S. J., Zhao A., Best S. J., Chandler J. D., Boyle D. B., Ramshaw I. A. Enhanced T cell immunogenicity and protective efficacy of a human immunodeficiency virus type 1 vaccine regimen consisting of consecutive priming with DNA and boosting with recombinant fowlpox virus. J. Virol. 72:1998;10180-10188.
3. Meltzer M. I., Cox N. J., Fukuda K. The economic impact of pandemic influenza in the United States: Priorities for intervention. Emerg. Inf. Dis. 5:1999;659-671.
4. Neirynek S., Deroo T., Saelens X., Vanlandschool P., Jou W. M., Fiers W. A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nature Med. 5:1999;1157.
5. Oldstone M. B. A., Tishon A., Eddleston M., de la Torre J. C., McKee T., Whitton J. L. Vaccination to prevent persistent viral infection. J. Virol. 67:1993;4372-4378.
6. Robinson H. L., Montefiori D. C., Johnson R. P. Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations. Nature Med. 5:1999;526-534.